Journal of Nuclear Medicine: 62 (10)

Index by author

October 1, 2021; Volume 62,Issue 10

Alazraki, Naomi
1. You have access
  Amnon (Amy) Piepsz, MD (1938–2021)
  Alain Prigent, M. Donald Blaufox, Andrew Taylor and Naomi Alazraki
  
  Journal of Nuclear Medicine October 1, 2021, 62 (10) 16N;
Allen-auerbach, Martin
1. You have access
  Safety of PSMA-Targeted Molecular Radioligand Therapy with ¹⁷⁷Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
  Jeremie Calais, Johannes Czernin, Pan Thin, Jeannine Gartmann, Kathleen Nguyen, Wesley R. Armstrong, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, Magnus Dahlbom, Beilei He, Rouzbeh Esfandiari, David Ranganathan, Ken Herrmann, Matthias Eiber, Wolfgang P. Fendler and Ebrahim Delpassand
  
  Journal of Nuclear Medicine October 1, 2021, 62 (10) 1447-1456; DOI: https://doi.org/10.2967/jnumed.121.262543
2. You have access
  Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with ¹⁷⁷Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
  Jeremie Calais, Andrei Gafita, Matthias Eiber, Wesley R. Armstrong, Jeannine Gartmann, Pan Thin, Kathleen Nguyen, Vincent Lok, Laura Gosa, Tristan Grogan, Rouzbeh Esfandiari, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, David Ranganathan, Roger Slavik, Magnus Dahlbom, Ken Herrmann, Ebrahim Delpassand, Wolfgang P. Fendler and Johannes Czernin
  
  Journal of Nuclear Medicine October 1, 2021, 62 (10) 1440-1446; DOI: https://doi.org/10.2967/jnumed.121.261982
Ametamey, Simon M.
1. You have access
  Identification of a PET Radiotracer for Imaging of the Folate Receptor-α: A Potential Tool to Select Patients for Targeted Tumor Therapy
  Patrycja Guzik, Hsin-Yu Fang, Luisa M. Deberle, Martina Benešová, Susan Cohrs, Silvan D. Boss, Simon M. Ametamey, Roger Schibli and Cristina Müller
  
  Journal of Nuclear Medicine October 1, 2021, 62 (10) 1475-1481; DOI: https://doi.org/10.2967/jnumed.120.255760
Anconina, Reut
1. You have access
  Quantitative ⁶⁸Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with ¹⁷⁷Lu-DOTATATE
  Claudia Ortega, Rebecca K.S. Wong, Josh Schaefferkoetter, Patrick Veit-Haibach, Sten Myrehaug, Rosalyn Juergens, David Laidley, Reut Anconina, Amy Liu and Ur Metser
  
  Journal of Nuclear Medicine October 1, 2021, 62 (10) 1406-1414; DOI: https://doi.org/10.2967/jnumed.120.256727
Antonarakis, Emmanuel S.
1. You have access
  Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted ¹⁸F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
  Katherine A. Zukotynski, Urban Emmenegger, Sebastien Hotte, Anil Kapoor, Wei Fu, Amanda L. Blackford, John Valliant, François Bénard, Chun K. Kim, Mark C. Markowski, Mario A. Eisenberger, Emmanuel S. Antonarakis, Kenneth J. Pienta, Michael A. Gorin, Matthew Lubanovic, Jihyun Kim, Martin G. Pomper, Steve Y. Cho and Steven P. Rowe
  
  Journal of Nuclear Medicine October 1, 2021, 62 (10) 1430-1437; DOI: https://doi.org/10.2967/jnumed.120.259069
Aparici, Carina Mari
1. You have access
  Prognostic Value of Bone Marrow Metabolism on Pretreatment ¹⁸F-FDG PET/CT in Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy
  Ryusuke Nakamoto, Lisa C. Zaba, Tie Liang, Sunil Arani Reddy, Guido Davidzon, Carina Mari Aparici, Judy Nguyen, Farshad Moradi, Andrei Iagaru and Benjamin Lewis Franc
  
  Journal of Nuclear Medicine October 1, 2021, 62 (10) 1380-1383; DOI: https://doi.org/10.2967/jnumed.120.254482
Armstrong, Wesley R.
1. You have access
  Safety of PSMA-Targeted Molecular Radioligand Therapy with ¹⁷⁷Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
  Jeremie Calais, Johannes Czernin, Pan Thin, Jeannine Gartmann, Kathleen Nguyen, Wesley R. Armstrong, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, Magnus Dahlbom, Beilei He, Rouzbeh Esfandiari, David Ranganathan, Ken Herrmann, Matthias Eiber, Wolfgang P. Fendler and Ebrahim Delpassand
  
  Journal of Nuclear Medicine October 1, 2021, 62 (10) 1447-1456; DOI: https://doi.org/10.2967/jnumed.121.262543
2. You have access
  Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with ¹⁷⁷Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
  Jeremie Calais, Andrei Gafita, Matthias Eiber, Wesley R. Armstrong, Jeannine Gartmann, Pan Thin, Kathleen Nguyen, Vincent Lok, Laura Gosa, Tristan Grogan, Rouzbeh Esfandiari, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, David Ranganathan, Roger Slavik, Magnus Dahlbom, Ken Herrmann, Ebrahim Delpassand, Wolfgang P. Fendler and Johannes Czernin
  
  Journal of Nuclear Medicine October 1, 2021, 62 (10) 1440-1446; DOI: https://doi.org/10.2967/jnumed.121.261982
Bahri, Shadfar
1. You have access
  Safety of PSMA-Targeted Molecular Radioligand Therapy with ¹⁷⁷Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
  Jeremie Calais, Johannes Czernin, Pan Thin, Jeannine Gartmann, Kathleen Nguyen, Wesley R. Armstrong, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, Magnus Dahlbom, Beilei He, Rouzbeh Esfandiari, David Ranganathan, Ken Herrmann, Matthias Eiber, Wolfgang P. Fendler and Ebrahim Delpassand
  
  Journal of Nuclear Medicine October 1, 2021, 62 (10) 1447-1456; DOI: https://doi.org/10.2967/jnumed.121.262543
2. You have access
  Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with ¹⁷⁷Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
  Jeremie Calais, Andrei Gafita, Matthias Eiber, Wesley R. Armstrong, Jeannine Gartmann, Pan Thin, Kathleen Nguyen, Vincent Lok, Laura Gosa, Tristan Grogan, Rouzbeh Esfandiari, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, David Ranganathan, Roger Slavik, Magnus Dahlbom, Ken Herrmann, Ebrahim Delpassand, Wolfgang P. Fendler and Johannes Czernin
  
  Journal of Nuclear Medicine October 1, 2021, 62 (10) 1440-1446; DOI: https://doi.org/10.2967/jnumed.121.261982
Bai, Chunmei
1. You have access
  A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of ⁶⁸Ga-NODAGA-LM3 and ⁶⁸Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors
  Wenjia Zhu, Yuejuan Cheng, Ru Jia, Hong Zhao, Chunmei Bai, Jianming Xu, Shaobo Yao and Li Huo
  
  Journal of Nuclear Medicine October 1, 2021, 62 (10) 1398-1405; DOI: https://doi.org/10.2967/jnumed.120.253096
Bal, Chandrasekhar
1. You have access
  Head-to-Head Comparison of ⁶⁸Ga-NOTA (⁶⁸Ga-NGUL) and ⁶⁸Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study
  Minseok Suh, Hyung-Jun Im, Hyun Gee Ryoo, Keon Wook Kang, Jae Min Jeong, Sneha Prakash, Sanjana Ballal, Madhav P. Yadav, Chandrasekhar Bal, Chang Wook Jeong, Cheol Kwak and Gi Jeong Cheon
  
  Journal of Nuclear Medicine October 1, 2021, 62 (10) 1457-1460; DOI: https://doi.org/10.2967/jnumed.120.258434

Main menu

User menu

Search

Index by author

Alazraki, Naomi

Allen-auerbach, Martin

Ametamey, Simon M.

Anconina, Reut

Antonarakis, Emmanuel S.

Aparici, Carina Mari

Armstrong, Wesley R.

Bahri, Shadfar

Bai, Chunmei

Bal, Chandrasekhar

In this issue

Issue highlights